Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?

  title={Relationship between Non-Alcoholic Fatty Liver Disease and Psoriasis: A Novel Hepato-Dermal Axis?},
  author={Alessandro Mantovani and Paolo Gisondi and Amedeo Lonardo and Giovanni Targher},
  journal={International Journal of Molecular Sciences},
Over the past 10 years, it has become increasingly evident that nonalcoholic fatty liver disease (NAFLD) is a multisystem disease that affects multiple extra-hepatic organ systems and interacts with the regulation of several metabolic and immunological pathways. In this review we discuss the rapidly expanding body of clinical and epidemiological evidence supporting a strong association between NAFLD and chronic plaque psoriasis. We also briefly discuss the possible biological mechanisms… 

Figures and Tables from this paper

Non-Alcoholic Fatty Liver Disease (NAFLD) in Patients with Psoriasis: A Review of the Hepatic Effects of Systemic Therapies

The hepatotoxic and hepatoprotective potential of systemic psoriasis therapies are summarized and non-alcoholic fatty liver disease (NAFLD) should receive clinical awareness as important comorbidity in Psoriasis.

Non‐alcoholic fatty liver disease and psoriasis – is there a shared proinflammatory network?

Early detection of non‐alcoholic fatty liver disease and a better understanding of its pathophysiology in the context of the systemic inflammation in psoriasis is important with regard to individualized treatment approaches.

Nonalcoholic fatty liver disease in patients with psoriasis: a consequence of systemic inflammatory burden?

Insight is provided into the possible role of chronic, low‐grade inflammation in the pathogenesis of nonalcoholic fatty liver disease (NAFLD) in patients with psoriasis and how biological therapies for Psoriasis may attenuate the systemic inflammatory process and progression of NAFLD.

Non-alcoholic fatty liver disease in patients with intestinal, pulmonary or skin diseases: Inflammatory cross-talk that needs a multidisciplinary approach

Prospective, controlled studies in NAFLD patients with extrahepatic comorbidities are required to demonstrate a causal relationship and also that appropriate multidisciplinary management improves these patients’ prognosis and survival.

Non-alcoholic fatty liver disease is associated with bacterial translocation and a higher inflammation response in psoriatic patients

The prevalence of NAFLD in patients with psoriasis is high and associated with a higher prevalence of metabolic syndrome features, bacterial translocation and a higher pro-inflammatory state.

Whether Screening for Non-alcoholic Fatty Liver Disease in Patients With Psoriasis Is Necessary: A Pilot Quality Improvement Project

A shared clinical pathway between the hepatology and dermatology departments to allow early identification and management of psoriasis patients for non-alcoholic fatty liver disease is developed and piloted on a prospective cohort of patients identified by the dermatology department.

Inflammation and lipid metabolism as a strong background connecting psoriasis and liver diseases

The study below presents the most recent data on the liver diseases and their pathogenesis in patients with psoriasis.

Bidirectional Association Between Psoriasis and Nonalcoholic Fatty Liver Disease: Real-World Evidence From Two Longitudinal Cohort Studies

Evidence supports a bidirectional association between NAFLD and psoriasis, especially in patients below the age of 40 years, and the correlation between the two diseases and the subsequent risk of disease development should be considered when caring for patients.

Non-alcoholic fatty liver disease in patients with psoriasis: therapeutic implications

All patients with psoriasis and insulin resistance and risk factors for metabolic syndrome should also been screened forNAFLD, and planning of the treatment options should always take into consideration the possible risks related to the liver, especially in patients with NAFLD.

Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis.

The effect of etanercept on hepatic fibrosis risk in patients with non-alcoholic fatty liver disease, metabolic syndrome, and psoriasis

Etanercept could be more efficacious to reduce the risk of developing hepatic fibrosis than PUVA therapy, and this preventive effect could be related to its anti-inflammatory and glucose homeostatic properties.

NAFLD: a multisystem disease.

Nonalcoholic fatty liver disease: a precursor of the metabolic syndrome.

Endocrine and liver interaction: the role of endocrine pathways in NASH

Clinicians should be aware of the potential role of endocrine disorders in patients with cryptogenic liver disease and of the effects of liver function on the endocrine system, as evidence that causally links hormonal disorders with hepatobiliary disease is reviewed.

Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis

Psoriasis patients appear to be at higher risk for diabetes mellitus and cardiovascular disease, which could likely be due to the effects of chronic inflammatory changes, in particular the secretion of proinflammatory cytokines.

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities

Non-pharmacological intervention such as diet, smoking cessation, and physical exercise could both improve the response to treatments for psoriasis and reduce the cardiovascular risk.

A novel animal model of metabolic syndrome with non-alcoholic fatty liver disease and skin inflammation

This simple mouse model can be utilized to evaluate a therapeutic strategy for the treatment of metabolic syndrome and NAFLD with skin inflammation and also to understand the nexus between these co-morbidities.